Breast Cancer

An at-home computerized program could be beneficial in treating cognitive impairment in cancer survivors.

Clinical hypnosis offers a non-pharmacological approach to managing chronic pain after cancer treatment.

The Food and Drug Administration (FDA) expanded the approved use of palbociclib (Ibrance) capsules plus endocrine therapy to treat male patients with hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer, according to an announcement by the agency.

The Food and Drug Administration decided to keep the device on the market, but wants to know more about the illnesses they may potentially be linked to.

The FDA announced today that it is working to update mammography regulations, expanding the amount of information that mammography facilities must give patients and healthcare professionals. In turn, this would result in more informed decision-making – especially when it comes to breast cancer diagnoses.

Preimplantation genetic diagnosis allows women of childbearing age to select embryos that do not have genetic mutations.

Oncology nurses are crucial in the management of cancer symptoms and treatment-related adverse events.

Many patients with cancer are prescribed opioids to manage post-surgical pain, putting oncology professionals in a prime position to affect the current epidemic.

An expert discusses the role oncology nurses play in managing the adverse events of patients with breast cancer.

Listen to the first-ever episode of the CURE Talks Cancer Podcast: Nursing Edition.

Not many people knew about male breast cancer when Sam Rivera was diagnosed, but he took the information from his nurses to spread awareness about the disease.

It’s an exciting time in the world of triple-negative breast cancer (TNBC), with treatments becoming more personalized to individual cancer subtypes, explained Adam Brufsky, MD, PhD.

Clinical trials can be very beneficial to patients and their families. However, barriers still exist in enrolling patients.

The FDA has granted an approval to PF-05280014 (Trazimera; trastuzumab-qyyp), a trastuzumab (Herceptin) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.

The Food and Drug Administration has granted an accelerated approval to the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC)

The FDA has approved subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, and alone or in combination with paclitaxel in patients with metastatic HER2-positive breast cancer who have received at least 1 prior chemotherapy regimen.

The FDA sent out a warning letter about using thermography in place of mammography to diagnose breast cancer. Here’s how oncology nurses can help.

Oncology Nursing News® spoke with CEO Linda Tantawi about addressing the needs of underserved communities and nurses can help to educate women in the Greater New York City area.

Although ET significantly reduces the risk of HRpositive/ HER2- negative early breast cancer, the cumulative risk of distant recurrence has remained steady for decades.

The FDA has granted an approval to SB3 (Ontruzant; trastuzumab-dttb), a trastuzumab (Herceptin) biosimilar, for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.

Women who took part in a supervised exercise program during adjuvant treatment for breast cancer had better cardiovascular function than women who did not participate in the program, according to the findings of a study presented at the San Antonio Breast Cancer Symposium (SABCS).

Combining the BCL-2 inhibitor venetoclax (Venclexta) with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor (ER)–positive and BCL-2–positive metastatic breast cancer.